JP2015519897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519897A5 JP2015519897A5 JP2015513275A JP2015513275A JP2015519897A5 JP 2015519897 A5 JP2015519897 A5 JP 2015519897A5 JP 2015513275 A JP2015513275 A JP 2015513275A JP 2015513275 A JP2015513275 A JP 2015513275A JP 2015519897 A5 JP2015519897 A5 JP 2015519897A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 55
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- 108060008539 Transglutaminase Proteins 0.000 claims 15
- 102000003601 transglutaminase Human genes 0.000 claims 15
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- LNLLNTMHVMIMOG-YUMQZZPRSA-N Gamma-glutamyl-Lysine Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O LNLLNTMHVMIMOG-YUMQZZPRSA-N 0.000 claims 2
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 102000047688 human TG Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 206010015124 Ergot poisoning Diseases 0.000 claims 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000008609 collagenous colitis Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- -1 for example Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000000463 red nucleus Anatomy 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1209096.5 | 2012-05-24 | ||
| GBGB1209096.5A GB201209096D0 (en) | 2012-05-24 | 2012-05-24 | Compounds |
| PCT/GB2013/051373 WO2013175229A1 (en) | 2012-05-24 | 2013-05-24 | Anti -transglutaminase 2 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104139A Division JP2018166510A (ja) | 2012-05-24 | 2018-05-30 | 抗トランスグルタミナーゼ２抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519897A JP2015519897A (ja) | 2015-07-16 |
| JP2015519897A5 true JP2015519897A5 (enExample) | 2016-06-30 |
| JP6411998B2 JP6411998B2 (ja) | 2018-10-24 |
Family
ID=46546551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513275A Active JP6411998B2 (ja) | 2012-05-24 | 2013-05-24 | 抗トランスグルタミナーゼ２抗体 |
| JP2018104139A Pending JP2018166510A (ja) | 2012-05-24 | 2018-05-30 | 抗トランスグルタミナーゼ２抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104139A Pending JP2018166510A (ja) | 2012-05-24 | 2018-05-30 | 抗トランスグルタミナーゼ２抗体 |
Country Status (39)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055235A (zh) * | 2019-05-14 | 2019-07-26 | 深圳市亚辉龙生物科技股份有限公司 | 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法 |
| FR3117599B1 (fr) * | 2020-12-16 | 2024-11-29 | Oreal | Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu |
| GB202115121D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115127D0 (en) | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202116665D0 (en) | 2021-11-18 | 2022-01-05 | UCB Biopharma SRL | Method for the treatment of a scleroderma disease |
| CN118354792A (zh) | 2021-11-18 | 2024-07-16 | Ucb生物制药有限责任公司 | 用于治疗进行性慢性间质性肺部疾病的方法 |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
| CN116515786B (zh) * | 2023-04-26 | 2024-05-28 | 广东医科大学 | 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用 |
| WO2025153465A1 (en) * | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912120A (en) | 1986-03-14 | 1990-03-27 | Syntex (U.S.A.) Inc. | 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| AU1268192A (en) | 1991-01-04 | 1992-08-17 | Board Of Regents, The University Of Texas System | Cloning and expression of tissue transglutaminases |
| AU6620596A (en) | 1996-07-25 | 1998-02-20 | Victoria University Of Manchester, The | Use of transglutaminase modulators to promote wound healing |
| GB0103024D0 (en) * | 2001-02-07 | 2001-03-21 | Rsr Ltd | Assay for Autoantibodies to tissue transglutaminase |
| CA2514942A1 (en) | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Methods and compositions for the treatment of parkinson's disease and other a-synucleinopathies |
| GB0314262D0 (en) | 2003-06-19 | 2003-07-23 | Univ Nottingham Trent | Novel compounds and methods of using the same |
| WO2006100679A2 (en) * | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| US8299040B2 (en) | 2006-10-18 | 2012-10-30 | Board Of Regents, The University Of Texas System | Methods for treating cancer targeting transglutaminase |
| CN102027013B (zh) * | 2008-04-24 | 2015-01-14 | 株式会社遗传科技 | 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用 |
| AU2010225460B2 (en) | 2009-03-19 | 2014-05-01 | Queensland University Of Technology | Targets for growth factor signalling and methods of therapy |
| HU0900199D0 (en) * | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis of gluten-induced autoimmune diseases |
| HU0900195D0 (en) | 2009-04-01 | 2009-06-29 | Debreceni Egyetem | Diagnosis and treatment of gluten-induced autoimmune diseases |
| WO2011151395A2 (en) | 2010-06-02 | 2011-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
-
2012
- 2012-05-24 GB GBGB1209096.5A patent/GB201209096D0/en not_active Ceased
-
2013
- 2013-05-24 EP EP13730049.7A patent/EP2855530B1/en active Active
- 2013-05-24 IN IN2231MUN2014 patent/IN2014MN02231A/en unknown
- 2013-05-24 PL PL19163818T patent/PL3521315T3/pl unknown
- 2013-05-24 BR BR112014029089-0A patent/BR112014029089B1/pt active IP Right Grant
- 2013-05-24 SM SM20210014T patent/SMT202100014T1/it unknown
- 2013-05-24 ES ES13730049T patent/ES2728856T3/es active Active
- 2013-05-24 PT PT191638188T patent/PT3521315T/pt unknown
- 2013-05-24 SM SM20190407T patent/SMT201900407T1/it unknown
- 2013-05-24 PL PL13730049T patent/PL2855530T3/pl unknown
- 2013-05-24 MY MYPI2014003271A patent/MY185966A/en unknown
- 2013-05-24 HU HUE19163818A patent/HUE052490T2/hu unknown
- 2013-05-24 LT LTEP13730049.7T patent/LT2855530T/lt unknown
- 2013-05-24 TR TR2019/06781T patent/TR201906781T4/tr unknown
- 2013-05-24 HU HUE13730049A patent/HUE045539T2/hu unknown
- 2013-05-24 PT PT13730049T patent/PT2855530T/pt unknown
- 2013-05-24 ES ES19163818T patent/ES2835383T3/es active Active
- 2013-05-24 CN CN201380026672.3A patent/CN104321346B/zh active Active
- 2013-05-24 AU AU2013265025A patent/AU2013265025B2/en active Active
- 2013-05-24 KR KR1020147036419A patent/KR102091223B1/ko active Active
- 2013-05-24 CA CA2874488A patent/CA2874488C/en active Active
- 2013-05-24 UA UAA201413832A patent/UA117657C2/uk unknown
- 2013-05-24 PE PE2014002040A patent/PE20150346A1/es active IP Right Grant
- 2013-05-24 SG SG11201407053YA patent/SG11201407053YA/en unknown
- 2013-05-24 EP EP19163818.8A patent/EP3521315B1/en active Active
- 2013-05-24 DK DK19163818.8T patent/DK3521315T3/da active
- 2013-05-24 HR HRP20191293TT patent/HRP20191293T1/hr unknown
- 2013-05-24 US US14/402,675 patent/US10005846B2/en active Active
- 2013-05-24 MX MX2014014264A patent/MX367517B/es active IP Right Grant
- 2013-05-24 RS RS20210033A patent/RS61286B1/sr unknown
- 2013-05-24 WO PCT/GB2013/051373 patent/WO2013175229A1/en not_active Ceased
- 2013-05-24 SI SI201331487T patent/SI2855530T1/sl unknown
- 2013-05-24 MA MA37670A patent/MA37670B1/fr unknown
- 2013-05-24 RS RS20190909A patent/RS59135B1/sr unknown
- 2013-05-24 EA EA201492162A patent/EA036810B1/ru not_active IP Right Cessation
- 2013-05-24 NZ NZ701424A patent/NZ701424A/en unknown
- 2013-05-24 LT LTEP19163818.8T patent/LT3521315T/lt unknown
- 2013-05-24 SI SI201331811T patent/SI3521315T1/sl unknown
- 2013-05-24 ME MEP-2019-181A patent/ME03393B/me unknown
- 2013-05-24 DK DK13730049.7T patent/DK2855530T3/da active
- 2013-05-24 JP JP2015513275A patent/JP6411998B2/ja active Active
-
2014
- 2014-10-28 IL IL235369A patent/IL235369B/en active IP Right Grant
- 2014-10-28 TN TN2014000458A patent/TN2014000458A1/fr unknown
- 2014-11-10 ZA ZA2014/08213A patent/ZA201408213B/en unknown
- 2014-11-18 CL CL2014003125A patent/CL2014003125A1/es unknown
- 2014-11-19 PH PH12014502582A patent/PH12014502582A1/en unknown
- 2014-12-12 EC ECIEPI201430942A patent/ECSP14030942A/es unknown
- 2014-12-23 CO CO14281628A patent/CO7151528A2/es unknown
-
2018
- 2018-05-23 US US15/987,611 patent/US10961319B2/en active Active
- 2018-05-30 JP JP2018104139A patent/JP2018166510A/ja active Pending
-
2019
- 2019-07-29 CY CY20191100807T patent/CY1121932T1/el unknown
-
2020
- 2020-12-14 US US17/121,541 patent/US11718686B2/en active Active
- 2020-12-23 HR HRP20202059TT patent/HRP20202059T1/hr unknown
-
2021
- 2021-01-11 CY CY20211100013T patent/CY1123926T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519897A5 (enExample) | ||
| EP3504240B1 (en) | Anti-tim-3 antibodies | |
| TWI751979B (zh) | 抗ｇａｒｐ抗體 | |
| JP2013056885A5 (enExample) | ||
| US20160280791A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| IL266893A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2020536109A5 (enExample) | ||
| US20190276534A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
| TWI699376B (zh) | 抗cd40抗體、其抗原結合片段及其醫藥用途 | |
| JP2020527356A (ja) | 抗ｃｄ１３７抗体 | |
| JP2018506277A5 (enExample) | ||
| RU2011124751A (ru) | Антитело против смет | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2022506719A (ja) | タウ認識抗体 | |
| RS59045B1 (sr) | Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15) | |
| TW201333033A (zh) | 雙可變域免疫球蛋白及其用途 | |
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| RU2012145232A (ru) | Гуманизированные антитела к cxcr4 для лечения рака | |
| HRP20202059T1 (hr) | Anti-transglutaminaza 2 antitijela | |
| JP2021500916A5 (enExample) | ||
| AU2016319433A1 (en) | Anti-EphA4 antibody | |
| JP2015518857A5 (enExample) | ||
| JP2014515600A5 (enExample) |